Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | ALB | P02768 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | PNP | P00491 | 7/20 | 0.44 |
| ▸ | HPRT1 | P00492 | 8/20 | 0.42 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2679155 | 0.76 | CDK1 (0.33) | ADORA3 | |
| SCHEMBL13813965 | 0.71 | PNP (0.50) | ALDH1A1LMNAALBMAPK1PNP | |
| SCHEMBL4250337 | 0.71 | PNP (0.50) | ALDH1A1LMNAALBMAPK1PNP | |
| SCHEMBL1573049 | 0.71 | PNP (0.50) | ALDH1A1LMNAALBMAPK1PNP | |
| SCHEMBL13801673 | 0.71 | PNP (0.50) | ALDH1A1LMNAALBMAPK1PNP | |
| SCHEMBL9308280 | 0.68 | ALDH1A1 (0.60) | ALDH1A1LMNAALBMAPK1PNP | |
| SCHEMBL9309643 | 0.67 | ALDH1A1 (0.60) | ALDH1A1LMNAALBMAPK1PNP | |
| SCHEMBL8340810 | 0.67 | ADORA3 (0.47) | ALDH1A1LMNAALBMAPK1PNP | |
| SCHEMBL8922846 | 0.67 | ALDH1A1 (0.69) | ALDH1A1LMNAALBMAPK1PNP | |
| SCHEMBL9309828 | 0.67 | ALDH1A1 (0.59) | ALDH1A1LMNAALBMAPK1PNP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8173662-B2 | Fused pyrimidines as inhibitors of nucleoside phosphorylases and nucleosidases | INDUSTRIAL RESEARCH LIMITED (NZ) | 2012-05-08 | — | — | US | disclosed |
| US-20090239885-A1 | Inhibitors of nucleoside phoshorylases and nucleosidases | BIOCRYST PHARMACEUTICALS, INC. | 2009-09-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090239885-A1 | Inhibitors of nucleoside phoshorylases and nucleosidases | PNP, MTAP, TYMP | ALDH1A1 2578/4885LMNA 2316/4885ALB 4210/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.